We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Luminex Corporation | NASDAQ:LMNX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 36.99 | 36.94 | 36.98 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
AUSTIN, Texas, Sept. 9 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) today announced that management will present at UBS Global Life Sciences Conference to be held September 20 - 22, 2010, in New York City, New York.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)
The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 8:00 a.m. Eastern time on Wednesday, September 22, 2010. The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the 'replay' link.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP(R) multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.
Contact: | Harriss T. Currie | |
Vice President, Finance and Chief Financial Officer | ||
512-219-8020 | ||
hcurrie@luminexcorp.com | ||
SOURCE Luminex Corporation
Copyright t. 9 PR Newswire
1 Year Luminex Chart |
1 Month Luminex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
